2022
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic review
2021
Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2014
Interventional Radiology Management of Unresectable Intrahepatic Cholangiocarcinoma
Talenfeld A, Holzwanger D, Madoff D. Interventional Radiology Management of Unresectable Intrahepatic Cholangiocarcinoma. Medical Radiology 2014, 201-223. DOI: 10.1007/978-3-642-40558-7_13.Peer-Reviewed Original ResearchInoperable intrahepatic cholangiocarcinomaTransarterial therapiesTransarterial chemoinfusionTransarterial radioembolizationIntrahepatic cholangiocarcinomaDrug-eluting bead transarterial chemoembolizationYttrium-90 transarterial radioembolizationChild A cirrhosisInterventional radiology managementUnresectable intrahepatic cholangiocarcinomaAbsence of cirrhosisMedian overall survivalLow tumor burdenBead transarterial chemoembolizationLow tumor gradeSmaller tumor sizeNormal performance statusPercutaneous ablative therapiesPercutaneous thermal ablationThermal ablationExtrahepatic diseaseConventional TACEOverall survivalPerformance statusPortal thrombus
2008
Strategies for Resection Using Portal Vein Embolization: Metastatic Liver Cancer
de Baere T, Madoff D, de Baere T, Elias D, Goere D, Kohneh-Sahrhi N. Strategies for Resection Using Portal Vein Embolization: Metastatic Liver Cancer. Seminars In Interventional Radiology 2008, 25: 123-131. PMID: 21326553, PMCID: PMC3036476, DOI: 10.1055/s-2008-1076680.Peer-Reviewed Original ResearchPortal vein embolizationFuture remnant liverMetastatic liver cancerLiver metastasesVein embolizationLiver cancerUse of PVEMultiple bilateral liver metastasesBilateral liver metastasesVolume of parenchymaPostoperative morbidityLiver resectionOncological conceptLiver hypertrophyRemnant liverPreoperative hypertrophyIndividual patientsTherapeutic strategiesFunctional assessmentResectionOncological landscapeThermal ablationEmbolizationPatientsMetastasis